NASDAQ:FLXN - Flexion Therapeutics Stock Price, Price Target & More

$25.17 +0.67 (+2.73 %)
(As of 04/26/2018 07:12 AM ET)
Previous Close$24.50
Today's Range$24.30 - $25.38
52-Week Range$16.51 - $32.25
Volume395,900 shs
Average Volume745,684 shs
Market Capitalization$921.68 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83

About Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics logoFlexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Debt-to-Equity Ratio0.58%
Current Ratio13.02%
Quick Ratio12.96%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales2,705.42
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book3.63

Profitability

EPS (Most Recent Fiscal Year)($4.16)
Net Income$-137,480,000.00
Net MarginsN/A
Return on Equity-68.45%
Return on Assets-40.11%

Miscellaneous

Employees251
Outstanding Shares37,620,000

How to Become a New Pot Stock Millionaire

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics (NASDAQ:FLXN) released its earnings results on Thursday, March, 8th. The specialty pharmaceutical company reported ($1.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.11) by $0.27. The specialty pharmaceutical company earned $0.36 million during the quarter, compared to the consensus estimate of $1.29 million. View Flexion Therapeutics' Earnings History.

What price target have analysts set for FLXN?

9 Wall Street analysts have issued 12-month price targets for Flexion Therapeutics' stock. Their predictions range from $36.00 to $570.00. On average, they expect Flexion Therapeutics' stock price to reach $99.00 in the next twelve months. View Analyst Ratings for Flexion Therapeutics.

Who are some of Flexion Therapeutics' key competitors?

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO, Principal Financial & Accounting Officer and Director (Age 66)
  • Dr. Neil Bodick M.D., Ph.D., Co-Founder & Chief Scientific Officer (Age 71)
  • Mr. Frederick W. Driscoll, Advisor (Age 67)
  • Scott Young, Sr. Director of Corp. Communications & Investor Relations
  • Ms. Carolyn Beaty Scimemi Esq., Chief Compliance Officer

Has Flexion Therapeutics been receiving favorable news coverage?

Media stories about FLXN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flexion Therapeutics earned a news impact score of 0.11 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 47.08 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $25.17.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $921.68 million and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (FLXN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  474
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Flexion Therapeutics (NASDAQ:FLXN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Flexion Therapeutics in the last 12 months. Their average twelve-month price target is $99.00, suggesting that the stock has a possible upside of 293.33%. The high price target for FLXN is $570.00 and the low price target for FLXN is $36.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.892.883.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $99.00$99.00$106.25$88.5020
Price Target Upside: 293.33% upside270.37% upside342.89% upside213.39% upside

Flexion Therapeutics (NASDAQ:FLXN) Consensus Price Target History

Price Target History for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ:FLXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2018Wells FargoSet Price TargetBuy$39.00LowView Rating Details
3/9/2018BMO Capital MarketsReiterated RatingOutperform -> Outperform$37.00 -> $36.00LowView Rating Details
2/1/2018Berenberg BankInitiated CoverageBuy$42.00HighView Rating Details
11/10/2017Northland SecuritiesReiterated RatingBuy$40.00N/AView Rating Details
10/29/2017Royal Bank of CanadaSet Price TargetBuy$44.00N/AView Rating Details
10/10/2017LaidlawReiterated RatingBuy$35.00 -> $38.00N/AView Rating Details
10/10/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$570.00N/AView Rating Details
10/9/2017Needham & Company LLCBoost Price TargetBuy -> Buy$36.00 -> $42.00N/AView Rating Details
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
12/22/2016Raymond JamesInitiated CoverageStrong-Buy$35.00N/AView Rating Details
11/8/2016BCSLower Price Target$0.65 -> $0.02N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Flexion Therapeutics (NASDAQ:FLXN) Earnings History and Estimates Chart

Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ:FLXN) Earnings Estimates

Current Year EPS Consensus Estimate: $-5.18 EPS
Next Year EPS Consensus Estimate: $-2.66 EPS

Flexion Therapeutics (NASDAQ FLXN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018Q4 2017($1.1110)($1.38)$1.29 million$0.36 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.98)($1.07)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.80)($0.91)ViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.75)ViewListenView Earnings Details
3/9/2017Q4 2016($0.71)($0.7850)ViewListenView Earnings Details
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
8/3/2016Q2($0.67)($0.63)ViewN/AView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
3/10/2016Q4 2015($0.58)($0.63)ViewN/AView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/23/2015Q4 2014($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.54)($0.45)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.55)($0.38)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.53)($0.86)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Flexion Therapeutics (NASDAQ:FLXN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Flexion Therapeutics (NASDAQ FLXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.98%
Institutional Ownership Percentage: 94.15%
Insider Trading History for Flexion Therapeutics (NASDAQ:FLXN)
Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ FLXN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Neil BodickInsiderBuy2,700$24.49$66,123.0064,605View SEC Filing  
11/8/2017Michael D ClaymanInsiderBuy5,000$23.60$118,000.0035,395View SEC Filing  
9/5/2017Yamo DenizInsiderBuy1,000$24.20$24,200.005,000View SEC Filing  
9/1/2017Yamo DenizInsiderBuy3,000$24.15$72,450.005,000View SEC Filing  
8/31/2017Yamo DenizInsiderBuy1,375$25.40$34,925.005,000View SEC Filing  
6/16/2017Mark StejbachDirectorBuy1,580$17.02$26,891.60View SEC Filing  
6/5/2017Michael D ClaymanInsiderBuy5,000$17.23$86,150.0020,146View SEC Filing  
4/17/2017Neil BodickInsiderSell5,000$28.23$141,150.0046,137View SEC Filing  
3/23/2017Frederick W DriscollCFOSell3,000$23.00$69,000.0010,777View SEC Filing  
3/17/2017Neil BodickInsiderSell5,000$20.41$102,050.0050,937View SEC Filing  
2/24/2017Neil BodickInsiderSell5,000$19.15$95,750.0055,937View SEC Filing  
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.0060,937View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.0065,937View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.0025,504View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.4730,721View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.7029,054View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.4027,388View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.0025,504View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.843,435View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.523,435View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.002,000View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.0013,568View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.0011,568View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.0075,937View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.009,568View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.0075,087View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.008,434View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.007,568View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.0072,987View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.005,934View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.005,568View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.0071,937View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.001,000View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Flexion Therapeutics (NASDAQ FLXN) News Headlines

Source:
DateHeadline
Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018
finance.yahoo.com - April 24 at 5:13 PM
Flexion Therapeutics (FLXN) Receives Consensus Recommendation of "Buy" from AnalystsFlexion Therapeutics (FLXN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 22 at 5:32 PM
Flexion (FLXN) Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA in Journal of Bone and Joint SurgeryFlexion (FLXN) Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA in Journal of Bone and Joint Surgery
www.streetinsider.com - April 19 at 8:46 AM
Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint SurgeryFlexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery
finance.yahoo.com - April 18 at 5:18 PM
 Analysts Expect Flexion Therapeutics (FLXN) Will Announce Quarterly Sales of $2.40 Million Analysts Expect Flexion Therapeutics (FLXN) Will Announce Quarterly Sales of $2.40 Million
www.americanbankingnews.com - April 18 at 4:32 AM
Zacks: Analysts Expect Flexion Therapeutics (FLXN) to Announce -$1.31 Earnings Per ShareZacks: Analysts Expect Flexion Therapeutics (FLXN) to Announce -$1.31 Earnings Per Share
www.americanbankingnews.com - April 16 at 3:24 AM
Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)
www.americanbankingnews.com - April 12 at 7:27 AM
Flexion Therapeutics (FLXN) Earns "Outperform" Rating from Royal Bank of CanadaFlexion Therapeutics (FLXN) Earns "Outperform" Rating from Royal Bank of Canada
www.americanbankingnews.com - April 11 at 2:55 PM
Zacks Investment Research Lowers Flexion Therapeutics (FLXN) to SellZacks Investment Research Lowers Flexion Therapeutics (FLXN) to Sell
www.americanbankingnews.com - April 9 at 11:27 PM
Northland Securities Reiterates Buy Rating for Flexion Therapeutics (FLXN)Northland Securities Reiterates Buy Rating for Flexion Therapeutics (FLXN)
www.americanbankingnews.com - April 8 at 12:40 AM
Flexion Therapeutics (FLXN) Upgraded to Hold by Zacks Investment ResearchFlexion Therapeutics (FLXN) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:52 PM
Why Flexion Therapeutics (FLXN) Could Be Positioned for a SlumpWhy Flexion Therapeutics (FLXN) Could Be Positioned for a Slump
www.zacks.com - April 6 at 5:14 PM
Flexion Therapeutics (FLXN) Downgraded to "Sell" at ValuEngineFlexion Therapeutics (FLXN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 6 at 1:54 PM
Royal Bank of Canada Reiterates "$44.00" Price Target for Flexion Therapeutics (FLXN)Royal Bank of Canada Reiterates "$44.00" Price Target for Flexion Therapeutics (FLXN)
www.americanbankingnews.com - April 4 at 4:44 PM
Small Cap to Large Cap Pharma Companies Positioning to Capitalize on Resurgent Biotech IndustrySmall Cap to Large Cap Pharma Companies Positioning to Capitalize on Resurgent Biotech Industry
www.bizjournals.com - April 4 at 3:49 PM
Form SC 13D/A Rice Midstream Partners Filed by: Harvest Fund Holdco L.P.Form SC 13D/A Rice Midstream Partners Filed by: Harvest Fund Holdco L.P.
www.streetinsider.com - April 4 at 8:50 AM
Flexion Therapeutics (FLXN) Given a $39.00 Price Target at Wells FargoFlexion Therapeutics (FLXN) Given a $39.00 Price Target at Wells Fargo
www.americanbankingnews.com - April 4 at 8:04 AM
Flexion Therapeutics (FLXN) Issued CMS Q code for ZilrettaFlexion Therapeutics (FLXN) Issued CMS Q code for Zilretta
www.streetinsider.com - April 3 at 8:57 AM
$2.80 Million in Sales Expected for Flexion Therapeutics Inc (FLXN) This Quarter$2.80 Million in Sales Expected for Flexion Therapeutics Inc (FLXN) This Quarter
www.americanbankingnews.com - April 1 at 4:42 AM
Flexion Therapeutics (FLXN) Upgraded to "Hold" by ValuEngineFlexion Therapeutics (FLXN) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - March 31 at 2:06 PM
Flexion Therapeutics (FLXN) Downgraded by Zacks Investment Research to SellFlexion Therapeutics (FLXN) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 31 at 12:10 PM
Zacks: Brokerages Expect Flexion Therapeutics Inc (FLXN) to Post -$1.24 Earnings Per ShareZacks: Brokerages Expect Flexion Therapeutics Inc (FLXN) to Post -$1.24 Earnings Per Share
www.americanbankingnews.com - March 30 at 9:05 AM
Zacks Investment Research Upgrades Flexion Therapeutics (FLXN) to HoldZacks Investment Research Upgrades Flexion Therapeutics (FLXN) to Hold
www.americanbankingnews.com - March 29 at 8:30 PM
Flexion Therapeutics Inc (FLXN) Given Consensus Rating of "Buy" by AnalystsFlexion Therapeutics Inc (FLXN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 28 at 5:42 PM
Flexion Therapeutics (FLXN) Upgraded to Sell at BidaskClubFlexion Therapeutics (FLXN) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - March 28 at 11:26 AM
Flexion Therapeutics (FLXN) Coverage Initiated by Analysts at Berenberg BankFlexion Therapeutics (FLXN) Coverage Initiated by Analysts at Berenberg Bank
www.americanbankingnews.com - March 25 at 9:48 PM
Flexion Therapeutics (FLXN) Upgraded to Hold at ValuEngineFlexion Therapeutics (FLXN) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 3:47 PM
Flexion Therapeutics (FLXN) Raised to "Sell" at BidaskClubFlexion Therapeutics (FLXN) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - March 24 at 8:22 PM
BidaskClub Downgrades Flexion Therapeutics (FLXN) to Strong SellBidaskClub Downgrades Flexion Therapeutics (FLXN) to Strong Sell
www.americanbankingnews.com - March 23 at 11:22 PM
Flexion Therapeutics to Present at Needham & Companys 17th Annual Healthcare ConferenceFlexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference
finance.yahoo.com - March 19 at 4:52 PM
Edited Transcript of FLXN earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of FLXN earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:46 AM
Flexion Therapeutics (FLXN) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowFlexion Therapeutics (FLXN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 5:38 PM
Flexion Therapeutics Inc (FLXN) Expected to Announce Quarterly Sales of $2.80 MillionFlexion Therapeutics Inc (FLXN) Expected to Announce Quarterly Sales of $2.80 Million
www.americanbankingnews.com - March 15 at 12:54 PM
Flexion Therapeutics (FLXN) Price Target Lowered to $36.00 at BMO Capital MarketsFlexion Therapeutics (FLXN) Price Target Lowered to $36.00 at BMO Capital Markets
www.americanbankingnews.com - March 9 at 9:07 PM
Why A Key Drug Launch Wasn't Enough To Help This Biotech StockWhy A Key Drug Launch Wasn't Enough To Help This Biotech Stock
finance.yahoo.com - March 9 at 6:13 PM
Flexion Therapeutics (FLXN) Announces Quarterly  Earnings Results, Misses Expectations By $0.27 EPSFlexion Therapeutics (FLXN) Announces Quarterly Earnings Results, Misses Expectations By $0.27 EPS
www.americanbankingnews.com - March 9 at 4:15 PM
Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsFlexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 6:06 PM
Flexion Therapeutics, Inc. to Host Earnings CallFlexion Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 6:06 PM
Flexion Therapeutics reports 4Q lossFlexion Therapeutics reports 4Q loss
finance.yahoo.com - March 8 at 6:06 PM
Flexion Therapeutics to Present at the Cowen 38th Annual Health Care ConferenceFlexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 5:57 PM
Bank of New York Mellon Corp Increases Stake in Flexion Therapeutics Inc (FLXN)Bank of New York Mellon Corp Increases Stake in Flexion Therapeutics Inc (FLXN)
www.americanbankingnews.com - March 5 at 4:54 AM
Flexion Therapeutics Inc (FLXN) Receives Consensus Rating of "Buy" from AnalystsFlexion Therapeutics Inc (FLXN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 3 at 5:38 PM
Gagnon Securities LLC Has $8.48 Million Position in Flexion Therapeutics Inc (FLXN)Gagnon Securities LLC Has $8.48 Million Position in Flexion Therapeutics Inc (FLXN)
www.americanbankingnews.com - March 3 at 5:10 PM
Wells Fargo & Company MN Acquires 1,555,093 Shares of Flexion Therapeutics Inc (FLXN)Wells Fargo & Company MN Acquires 1,555,093 Shares of Flexion Therapeutics Inc (FLXN)
www.americanbankingnews.com - March 2 at 7:38 PM
Gagnon Advisors LLC Grows Stake in Flexion Therapeutics Inc (FLXN)Gagnon Advisors LLC Grows Stake in Flexion Therapeutics Inc (FLXN)
www.americanbankingnews.com - March 2 at 5:42 PM
Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference - GlobeNewswire (press release)Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:39 AM
104,855 Shares in Flexion Therapeutics Inc (FLXN) Purchased by Brant Point Investment Management LLC104,855 Shares in Flexion Therapeutics Inc (FLXN) Purchased by Brant Point Investment Management LLC
www.americanbankingnews.com - March 1 at 5:22 AM
Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors ConferenceFlexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference
finance.yahoo.com - February 28 at 5:36 PM
Schroder Investment Management Group Buys 89,806 Shares of Flexion Therapeutics Inc (FLXN)Schroder Investment Management Group Buys 89,806 Shares of Flexion Therapeutics Inc (FLXN)
www.americanbankingnews.com - February 27 at 11:52 AM
Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018
finance.yahoo.com - February 26 at 5:24 PM

SEC Filings

Flexion Therapeutics (NASDAQ:FLXN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Flexion Therapeutics (NASDAQ:FLXN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Flexion Therapeutics (NASDAQ FLXN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.